Loading cancer entity…
Loading cancer entity…
Clinical trials
20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse | not yet recruiting | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07502287 | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma(DUAL-NK-NB) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 |
| clinicaltrials |
| NCT04385277 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | active not recruiting | Phase 2 | 41 | Children's Oncology GroupNETWORK | 4 | Oct 27, 2025 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials